

THE PRODUCTION OF EXO- AND ENDO-  $\beta$ - GLUCAN  
FROM MALAYSIAN *Ganoderma lucidum* IN A  
REPEATED BATCH FERMENTATION AND ITS ROLE  
AS  $\alpha$ -GLUCOSIDASE INHIBITOR

BY

NUR RAIHAN BINTI ABDULLAH

A thesis submitted in fulfilment of the requirement for the  
degree of Master of Science

Kulliyyah of Science  
International Islamic University Malaysia

JULY 2022

## ABSTRACT

Polysaccharides extracted from *Ganoderma lucidum* (GL) were reported previously as promising anti-diabetic drugs. They have shown inhibition of glucosidase enzyme, one of the primary targets for type 2 diabetes mellitus (T2DM) treatment. This study aims to identify the roles of EPS and ENS extracted from GL in inhibiting the  $\alpha$ -glucosidase enzyme. Upscale production of GL was done using a 10L bioreactor. The zebrafish embryo toxicity test was carried out based on OECD guidelines. For diabetes induction, the adult zebrafish (3–4 months of age) were overfed and induced with three doses of 350 mg/kg streptozotocin (STZ) by intraperitoneal injection (IP) on three different days (Day 1, 3, and 5). Oral sucrose tolerance test (OSTT) and anti-diabetic activity of exo- $\beta$ -glucan (EPS-BG) and endo- $\beta$ -glucan (ENS-BG) were evaluated (Day 7) using the developed model (n = 15). This study showed both EPS-BG ( $IC_{50} = 0.1575$  mg/mL) and ENS-BG ( $IC_{50} = 0.3479$  mg/mL) demonstrated a strong inhibition towards  $\alpha$ -glucosidase activity similar to the clinically approved  $\alpha$ -glucosidase inhibitor, acarbose ( $IC_{50} = 0.8107$  mg/mL). ENS is non-toxic towards zebrafish embryos with  $LC_{50}$  of 0.92 mg/mL and showed no significant changes in zebrafish embryo hatching and normal heart rate as compared to untreated embryos (161 beats/min). Teratogenic effects of ENS (<1.0 mg/mL) on zebrafish embryonic development were not observed. The DM model of zebrafish were acquired after the third dose of STZ with a fasting BGL of  $8.98 \pm 0.28$  mmol/L compared to the normal healthy group ( $4.23 \pm 0.62$  mmol/L). The BGL of DM zebrafish after 30 minutes treated with EPS-BG and ENS-BG showed a significant reduction. Both EPS-BG and ENS-BG significantly reduced DM zebrafish's peak blood glucose and area under the curve in OSTT. Hence, from the study, GL mycelial pellets withstood seven cycles of long fermentation conditions and possessed anti-diabetic properties, which suits large-scale natural drug fermentation. EPS-BG and ENS-BG extracted from GL showed promising inhibition of the  $\alpha$ -glucosidase enzyme and are considered non-toxic in ZE. Moreover, EPS-BG and ENS-BG reduced blood glucose levels and inhibited hyperglycaemia in DM zebrafish.

## ملخص البحث

بينت دراسات سابقة أنّ السكريات المستخرجة من فطر الريشي (GL) تعدّ أدوية واعدة لمعالجة مرض السكري. فقد أظهرت قدرتها على تثبيط إنزيم الجلوكوزيداز، وهو أحد الطرق الرئيسية لعلاج مرض السكري من النوع ٢. تهدف هذه الدراسة إلى تحديد دور (EPS) و (ENS) المستخلصان من (GL) في تثبيط إنزيم ( $\alpha$ -glucosidase). تم تحفيز إنتاج (GL) باستخدام مفاعل حيوي سعة ١٠ لتر. تم إجراء اختبار سمية جنين السمك الزرد بإرشادات من منظمة التعاون الاقتصادي والتنمية (OECD). لتحفيز الإصابة بمرض السكري، تُطعم أسماك الزرد البالغة (من 3 إلى 4 أشهر) حتى التخمّة ثم تحقن بثلاث جرعات من ٣٥٠ مجم / كجم من الستربتوزوتوسين (STZ) عن طريق الحقن داخل الصفاق (IP) في ثلاثة أيام مختلفة (اليوم ١ و ٣ و ٥). قيم اختبار تحمّل السكر الفموي (OSTT) والنشاط المضاد لمرض السكري لبيتا دي جلوكان الخارجي وبيتا دي جلوكان الداخلي كانت مرتفعة (يوم ٧) باستخدام التّموذج المطور (n = 15). أظهرت هذه الدراسة أن كل من (IC<sub>50</sub> = 0.1575 (EPS-BG) و (mg/ml) (ENS-BG) (IC<sub>50</sub> = 0.3479 mg/ml) يعد مثبّطاً قوياً تجاه نشاط  $\alpha$ -glucosidase (glucosidase inhibitor) المعتمد سريريّاً، acarbose (IC<sub>50</sub> = 0.8107 mg / mL). (ENS) غير سام تجاه أجنة السمك الزرد مع (LC<sub>50</sub>) من (0.92 mg/ml) ولا يظهر أي تغييرات مهمة في فقس أجنة سمك الزرد (ZE) ومعدل ضربات قلب طبيعية مقارنة بالأجنة غير المعالجة (161 beats/min). لم يتم ملاحظة تأثيرات متعلقة بالتشوهات الجنينية ENS (<1.0 mg/ml) على التطور الجنيني لأسماك الزرد. تم الحصول على نموذج (DM) من سمك الزرد بعد الجرعة الثالثة من (STZ) مع صيام (BGL) (8.98 ± 0.28 mmol/L) مقارنة بالمجموعة الصحية العادية (4.23 ± 0.62 mmol/L). أظهر (BGL) لأسماك الزرد (DM) انخفاضاً كبيراً بعد 30 دقيقة من المعالجة بـ (EPS-BG) و (ENS-BG). خفض كل من (EPS-BG) و (ENS-BG) بشكل كبير ذروة جلوكوز الدم في أسماك الزرد (DM) والمنطقة الواقعة تحت المنحنى في (OSTT). في الدراسة، صمدت كرات الأفطوري (GL mycelial pellets) سبع دورات من حالات التخمر الطويلة وامتلكت خصائص مضادة لمرض السكري، والتي تناسب تخمر الأدوية الطبيعية على نطاق واسع. أظهر (EPS-BG) و (ENS-BG) المستخلصان من (GL) تثبيطاً مباشراً لإنزيم ( $\alpha$ -glucosidase) ويعتبران غير سامين في استخدامهما لأسماك الزرد (ZE). بالإضافة إلى أنّ (EPS-BG) و (ENS-BG) استطاعا تخفيض مستويات الجلوكوز في الدم وتثبيط ارتفاع السكر في الدم في سمك الزرد (DM).

## APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Science.

.....  
Mohd Faez Sharif  
Supervisor

.....  
Mohd Hamzah bin Mohd Nasir  
Co-Supervisor

.....  
Nur Hafizah Azizan  
Co-Supervisor

.....  
Wan Abd Al-Qadr Imad Wan  
Mohtar  
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Science.

.....  
Normah binti Haron  
Examiner


.....  
Zul Ilham Bin Zulkiflee Lubes  
External Examiner

This thesis was submitted to the Department of Biotechnology and is accepted as a fulfilment of the requirement for the degree of Master of Science.

.....  
Tengku Haziya Amin Tengku  
Abdul Hamid  
Head, Department of  
Biotechnology

This thesis was submitted to the Kulliyah of Science and is accepted as a fulfillment of the requirement for the degree of Master of Science.

.....  
Jesni Bin Shamsul Shaari  
Dean, Kulliyah of Science




## DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Nur Raihan binti Abdullah

Signature ..... *Raihan* ..... Date .....



**INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA**

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF  
FAIR USE OF UNPUBLISHED RESEARCH**

**THE PRODUCTION OF EXO- AND ENDO-  $\beta$ - GLUCAN FROM  
MALAYSIAN *Ganoderma lucidum* BY A REPEATED BATCH  
FERMENTATION AND ITS ROLE AS  $\alpha$ -GLUCOSIDASE  
INHIBITOR**

I declare that the copyright holder of this thesis is jointly owned by the student and IIUM.

Copyright © 2022 by Nur Raihan binti Abdullah and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may only be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieval system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Nur Raihan binti Abdullah.

*Raihan*.....

Signature

.....

Date

## ACKNOWLEDGEMENTS

First and Foremost, Alhamdulillah and praise to Allah, the Almighty, the greatest of all, on whom we ultimately depend for sustenance and guidance. I owe you utmost gratitude for providing me with the opportunity, mental strength, and perseverance necessary to complete my master's degree. "Call upon Me; I will respond to you"- (40:60). Thank you for always being with me. Alhamdulillah!

My highest appreciation is given to my supervisors, Dr. Mohd Faez Sharif, Dr. Nur Hafizah Azizan, Dr. Mohd Hamzah Bin Mohd Nasir, and Dr. Wan Abd Al Qadr Imad Wan Mohtar for unwavering support, mentorship, patience, and encouragement. Thank you for not giving up on me throughout this study.

I would like to extend my gratitude to KOS and CREAM staff, for helping me book and use the laboratory and equipment. Thank you to my Advance cell biology laboratory colleagues, Ms. Asmadamia, Mr. Ismail, and Ms. Aqila, for their assistance in settling into a new environment. To my dear new friends, Ms. Ibrah, Ms. Khairiah, and the rest of the gang, I express my heartfelt gratitude and thanks. It was because of you guys that my lonely lab work days in the zebrafish laboratory began to be more enjoyable and amazing. Not forgotten, supportive staff from UM, Ms. Asyikin, Ms. Rusidah, Ms. Sarah, and Mr. Nadzrul and laboratory partners from Functional Omics and Bioprocessing Laboratory, Mr. Sugendran, Ms. Joshini, Ms. Aikim, Ms. Sassi and Ms. Amalia for the continued support and memories. Special thanks to Ms. Rokhiyah from Agro-Biotechnology Institute for hands-on training to use Nuclear Magnetic Resonance.

Most importantly, none of this could have happened without my family. My mother offered her prayers and encouragement. Since the beginning of time, she has been nice and supportive to me. This thesis represents as a tribute to my family's gratitude for unwavering love and support. Not to mention my unsung heroes who are always there to pray for me and give me motivation to keep going in life. I was finally able to graduate. This is never easy; blood, sweat, and tears. Thank you! A final word of gratitude is reserved for Yayasan Terengganu, for providing financial support since my second semester.



## TABLE OF CONTENT

Abstract .....	ii
Abstract in Arabic .....	iii
Approval Page.....	iv
Declaration .....	vi
Acknowledgements.....	viii
Table of Content .....	ix
List of Tables .....	xiii
List of Figures .....	xiv
List of Symbols .....	xvii
List of Abbreviation .....	xviii
<b>CHAPTER ONE: INTRODUCTION .....</b>	<b>1</b>
1.1 Background of the study .....	1
1.2 Problem statement .....	3
1.3 Research objectives .....	3
1.4 Hypothesis .....	4
1.5 Significance of the study .....	4
1.6 Conceptual framework.....	5
<b>CHAPTER TWO: LITERATURE REVIEW.....</b>	<b>6</b>
2.1 <i>Ganoderma lucidum</i> .....	6
2.1.1 <i>Ganoderma lucidum</i> strain QRS 5120 .....	6
2.1.2 Fermentation strategies.....	8
2.1.3 Repeated-batch fermentation (RBF).....	8
2.1.4 Morphology of <i>Ganoderma lucidum</i> in liquid media.....	9
2.1.5 Polysaccharide and beta-glucan .....	9
2.1.6 Current research on <i>Ganoderma lucidum</i> related to diabetes mellitus study.....	10
2.2 Diabetes mellitus (DM) .....	12
2.2.1 Diagnosis of diabetes mellitus.....	12
2.2.2 Diabetes mellitus statistic in Malaysia .....	13
2.2.3 Type 1 Diabetes mellitus (T1DM) .....	13
2.2.4 Type 2 Diabetes mellitus (T2DM) .....	14
2.2.5 Blood glucose homeostasis.....	14

2.3	Oral Medication for Type 2 Diabetes mellitus .....	15
2.3.1	Side effects of oral medicine for type 2 diabetes mellitus.....	17
2.3.2	$\alpha$ -glucosidase inhibitor .....	19
2.4	Animal model used for diabetes mellitus study.....	20
2.4.1	Zebrafish.....	20
<b>CHAPTER THREE: MATERIALS AND METHODS .....</b>		<b>22</b>
3.1	Chemicals and Reagents .....	22
3.2	Microorganism.....	22
3.3	Liquid Fermentation .....	23
3.3.1	Fermentation in shake flask.....	23
3.3.2	Repeated-batch fermentation (RBF).....	24
3.3.3	Upscale production using bioreactor .....	25
3.4	Analytical methods for polysaccharides .....	26
3.4.1	Mycelium biomass.....	26
3.4.2	Exopolysaccharide (EPS) extraction .....	26
3.4.3	Endopolysaccharide (ENS) extraction.....	27
3.4.4	Kinetics calculation .....	27
3.4.5	Residual glucose determination.....	28
3.4.6	Image analysis .....	28
3.5	Sulphation of EPS and ENS .....	29
3.6	Characterisation of B-glucan using Fourier Transform Infrared Spectroscopy (FTIR) .....	30
3.7	Proton nuclear magnetic resonance ( $^1\text{H-NMR}$ ).....	30
3.8	$\alpha$ -glucosidase enzyme inhibition assay.....	31
3.8.1	$\alpha$ -glucosidase enzyme inhibition activity .....	31
3.8.2	Enzyme kinetics of $\alpha$ -glucosidase .....	32
3.9	Zebrafish embryo toxicity (ZFET) assay.....	32
3.9.1	Ethics declaration .....	32
3.9.2	Zebrafish Maintenance and Breeding.....	32
3.9.1	Sample preparations for toxicity test.....	33
3.9.2	Zebrafish embryo toxicity test (ZFET).....	33
3.10	<i>In vivo</i> study of diabetes mellitus using zebrafish .....	34
3.10.1	Ethical statement.....	34
3.10.2	Zebrafish husbandry and experimental design .....	34
3.10.3	Pain management (Anaesthesia / Euthanasia method).....	36
3.10.4	A weight measurement of zebrafish .....	37

3.10.5	Induction of diabetes using overfed and streptozotocin injection method .....	37
3.10.6	Repeated blood collection for a blood glucose reading.....	40
3.10.7	Oral Administration of EPS-BG and ENS-BG using force-feed method .....	42
3.10.8	Oral sucrose tolerance test (OSTT) .....	43
3.11	Statistical analysis.....	43

## **CHAPTER FOUR: RESULTS AND DISCUSSION ..... 44**

4.1	Pellet diameter of <i>Ganoderma lucidum</i> in a repeated-batch fermentation .....	44
4.1.1	Determination of broth replacement time point and broth replacement ratio .....	44
4.1.2	Pellet morphology and diameter of <i>G. lucidum</i> for biomass production in RBF .....	47
4.1.3	Pellet morphology and diameter of <i>G. lucidum</i> for EPS production in RBF .....	49
4.1.4	Pellet morphology and diameter of <i>G. lucidum</i> for ENS production in RBF .....	51
4.1.5	Pellet morphological comparison of biomass-EPS-ENS production of <i>G. lucidum</i> in RBF .....	53
4.1.6	Pellet morphological comparison of the current work on <i>G. lucidum</i> for biomass-EPS-ENS production in RBF based on available literature .....	55
4.2	Characterisation of EPS and ENS of <i>Ganoderma lucidum</i> .....	58
4.2.1	FTIR analysis of EPS and ENS .....	58
4.2.2	<sup>1</sup> H-NMR spectroscopic analysis of EPS and ENS .....	59
4.3	<i>In vitro</i> $\alpha$ -glucosidase inhibitory assay .....	61
4.3.1	Kinetics of $\alpha$ -glucosidase enzyme inhibition .....	65
4.4	Zebrafish embryo toxicity (ZFET) assay .....	67
4.4.1	Zebrafish embryo survival rate after ENS-BG exposure .....	67
4.4.2	Zebrafish embryos mortality rate after ENS-BG exposure .....	68
4.4.3	Zebrafish embryos hatching rate after ENS-BG exposure .....	70
4.4.4	Zebrafish embryos heart rate after ENS-BG exposure .....	71
4.4.5	Morphology and development of the larvae and zebrafish embryos after ENS-BG exposure .....	72
4.4.6	Non-toxicity assessment of endopolysaccharide (ENS-BG) from the mushroom <i>Ganoderma lucidum</i> .....	74
4.5	<i>In vivo</i> study of EPS-BG and ENS-BG as antidiabetic drugs using induced diabetic adult zebrafish .....	78
4.5.1	Development of the induced diabetes zebrafish model .....	78

4.5.2 Oral sucrose tolerance test and anti-diabetic activity of EPS-BG and ENS-BG on induced diabetic zebrafish .....	81
<b>CHAPTER FIVE: CONCLUSION .....</b>	<b>86</b>
5.1 Recommendation for future works .....	86
<b>REFERENCES.....</b>	<b>87</b>
<b>APPENDIX I: SUPPLEMENTARY DATA.....</b>	<b>109</b>
<b>APPENDIX II: ETHICAL APPROVAL.....</b>	<b>110</b>
<b>APPENDIX III: PUBLICATION.....</b>	<b>111</b>



## LIST OF TABLES

Table 2.1	Recent studies on <i>Ganoderma lucidum</i> related diabetes mellitus.	11
Table 2.2	Blood glucose reading limit	13
Table 2.3.	Anti-hyperglycaemic medications and their mechanism of actions	16
Table 2.4	Side effects of synthetic anti-diabetic medicines.	17
Table 4.1	Comparison of the current work on <i>Ganoderma sp.</i> fermentation regarding biomass, exopolysaccharide (EPS), and endopolysaccharide (ENS) production and its morphology.	56
Table 4.2	Estimated IC <sub>50</sub> value and the percentage of $\alpha$ -glucosidase enzyme inhibition activity by EPS-BG, ENS-BG, and acarbose.	63
Table 4.3	<i>Ganoderma lucidum</i> inhibition activity toward $\alpha$ -glucosidase enzyme.	64
Table 4.4	Non-toxicity assessment of polysaccharides from <i>G. lucidum</i> .	77

## LIST OF FIGURES

Figure 1.1	Conceptual framework	5
Figure 2.1	Morphology of <i>Ganoderma lucidum</i> QRS 5120 used in this study; (a) fruiting body in solid state fermentation, (b) detached fruiting body, and (c) hymenium pores at the back of the fruiting body	7
Figure 2.2	Schematic representation of fungal morphologies in suspension culture (adopted from Wan-Mohtar, (2016).	9
Figure 3.1	<i>Ganoderma lucidum</i> Strain QRS 5120 (a) on PDA plate and (b) fruiting body by solid-state fermentation.	23
Figure 3.2	Liquid fermentation in shake flask	24
Figure 3.3	Repeated batch fermentation.	25
Figure 3.4	Upscale production of <i>Ganoderma lucidum</i> using bioreactor at (a) day 1 and (b) day 6.	25
Figure 3.5	Extraction of EPS; (a) cold ethanol extraction and (b) jelly-like structure of EPS after treated with cold ethanol.	26
Figure 3.6	Extraction of ENS; (a) dried mycelium, (b) hot water extraction, and (c) cold ethanol precipitation.	27
Figure 3.7	Pellet placed on Microscopic Objective Stage Micrometre Calibration Slide 10mm/100 0.1mm C7 (Image was taken at 4X magnification under LEICA DFC295 microscope)	29
Figure 3.8	Structure of EPS and ENS (a) with and without sulphation process and bigger picture of dried (b) EPS and (c) ENS.	30
Figure 3.9	Experimental design for <i>in vivo</i> study using adult zebrafish.	35
Figure 3.10	The aquarium setup for each group of zebrafish treatment.	35
Figure 3.11	Set up for anesthetization of zebrafish.	36
Figure 3.12	Set up for weigh measurement of zebrafish.	37
Figure 3.13	STZ induction timeline in zebrafish.	39
Figure 3.14	Intraperitoneal injection of STZ into zebrafish.	39
Figure 3.15	Set up for STZ injection and blood collection.	40
Figure 3.16	List of items needed for blood collection; z-fish needle, glucometer, glucose strip, parafilm.	41

Figure 3.17	The blood collection site along the body axis and posterior to the anus	41
Figure 3.18	Collection of the zebrafish blood using Z-fish needle.	42
Figure 3.19	Measurement of blood glucose level using Accu-Chek glucometer.	42
Figure 3.20	Force-feed method for administration of sucrose and treatment.	43
Figure 4.1	Batch fermentation growth curves and glucose consumption for the generation of broth replacement time point (BRTP) for biomass 7-9-11(left blue box), exopolysaccharide (EPS) 9-11-13 (middle green box), and endopolysaccharide (ENS) 11-13-15 (right red box) of <i>Ganoderma lucidum</i> strain QRS 5120.	46
Figure 4.2	Pellet morphology (A) and diameters (B) of <i>G. lucidum</i> QRS 5120 for biomass production in repeated-batch fermentation at broth replacement time point (BRTP) Day 11 and broth replacement ratio (BRR) of 75%.	48
Figure 4.3	Pellet morphology (A) and diameters (B) of <i>G. lucidum</i> QRS 5120 for exopolysaccharide (EPS) production in repeated-batch fermentation at broth replacement time point (BRTP) Day 13 and broth replacement ratio (BRR) of 75%.	50
Figure 4.4	Pellet morphology (A) and diameters (B) of <i>G. lucidum</i> QRS 5120 for endopolysaccharide (ENS) production in repeated-batch fermentation at broth replacement time point (BRTP) Day 13 and broth replacement ratio (BRR) of 90%.	52
Figure 4.5	Comparison for production and pellet morphology of biomass, exopolysaccharide (EPS), and endopolysaccharide (ENS) for <i>G. lucidum</i> QRS 5120 in repeated-batch fermentation.	54
Figure 4.6	FTIR spectra result of $\beta$ -glucan (A: crude exopolysaccharide (EPS), B: crude endopolysaccharide (ENS)) from the mycelium <i>G. lucidum</i> QRS 5120 in a repeated-batch fermentation.	59
Figure 4.7	$^1\text{H-NMR}$ spectra of $\beta$ -D-glucan (BG) of (A) laminarin ( <i>Laminaria digitata</i> ) standard, (B) exopolysaccharide (EPS), and (C) endopolysaccharide (ENS) derived from <i>G. lucidum</i> QRS5120 mycelium in a repeated-batch fermentation.	60
Figure 4.8	Michelis-Menten plots of (A) EPS-BG and (B) ENS-BG.	65

Figure 4.9	Lineweaver-Burk plots of (A) EPS-BG and (B) ENS-BG.	66
Figure 4.10	Survival rate of zebrafish embryos at 0 to 120 hours after exposure to ENS-BG at concentrations of 0.06-4 mg/mL.	68
Figure 4.11	Effect of ENS-BG at concentrations of 0.06-4 mg/mL on zebrafish embryos mortality rate after 120 hours of post-fertilization (hpf).	69
Figure 4.12	Hatching rate of zebrafish embryos at 0 to 120 hours of post-exposure with ENS-BG at concentrations of 0.06-4 mg/mL.	71
Figure 4.13	Effect of ENS-BG at concentrations of 0.06-4 mg/mL on the heart rate of zebrafish embryos at 96 hpf.	72
Figure 4.14	Image of zebrafish embryo and larvae development after treated with ENS-BG at a concentration of 0.5 mg/mL.	73
Figure 4.15	Image of zebrafish embryo and larvae development after treated with ENS-BG at a concentration of 4.0 mg/mL.	74
Figure 4.16	Fasting blood glucose level of zebrafish analysed at different times after the injection of STZ (0.35 mg/g).	80
Figure 4.17	Fasting blood glucose level of zebrafish at day 7 (Two days after the third dose of STZ injection).	81
Figure 4.18	Effect of EPS-BG, ENS-BG, and acarbose on oral sucrose tolerance test.	84
Figure 4.19	Area under the curve (AUC) of zebrafish blood glucose level after oral sucrose administration.	85



## LIST OF SYMBOLS

$^{\circ}\text{C}$	Degree Celsius
g	Grams
h	Hour
$K_m$	Michaelis-Menten constant
L	Liter
mg	Milligrams
min	Minutes
mL	Milliliter
rpm	Revolutions per minute
$V_{\max}$	Maximum velocity
v/v	Volume per volume
VVM	Volume of air per volume of culture per minute
$\alpha$	Alpha
$\beta$	Beta
$\mu\text{g}$	Micrograms
$\mu\text{m}$	Micrometers (microns)

## LIST OF ABBREVIATION

AGI	$\alpha$ -glucosidase inhibitor
BGL	Blood glucose level
BRR	Broth replacement ratio
BRTTP	Broth replacement time point
DM	Diabetes mellitus
ENS	Endopolysaccharide
ENS-BG	Endo- $\beta$ -Glucan
EPS	Exopolysaccharide
EPS-BG	Exo- $\beta$ -Glucan
FTIR	Fourier Transform Infrared Spectroscopy
GL	<i>Ganoderma lucidum</i>
Hpf	Hour post-fertilization
IP	Intraperitoneal injection
NMR	Nuclear Magnetic Resonance
OECD	Organization for Economic Cooperation and Development
OSTT	Oral sucrose tolerance test
RBF	Repeated batch fermentation
SLF	Submerged liquid fermentation
STZ	Streptozotocin
ZE	Zebrafish embryo
ZFET	Zebrafish embryo toxicity test

# CHAPTER ONE

## INTRODUCTION

### 1.1 BACKGROUND OF THE STUDY

*Ganoderma lucidum* (*G. lucidum*) is one of the broadly utilized species in the biochemical and pharmaceutical fields. The research grew rapidly on the metabolite or complex produced, for example, ganoderic acid and polysaccharide for their medicinal convenience and was considered as a “remedy that could resuscitate the dead” (R. Ahmad et al., 2021; Baby et al., 2015; Du et al., 2021; Zhou et al., 2015). These days, *Ganoderma* has been utilized to prevent and treat numerous kinds of disorders and well-being items that are accepted to have anti-cancer properties, anti-ageing, and are hostile to microbial or against viral capacities. These products of *Ganoderma* are accessible, particularly in East Asia and the USA (Paterson, 2006; Seweryn et al., 2021). The amount of publication that discussed on the separation, bioactivity, and production of bioactive auxiliary metabolites of *G. lucidum* has expanded due to their extraordinary healthy benefit, as well as their bottomless and interesting optional metabolites as a promising potential library for new medication disclosure.

Two methods used to cultivate this mushroom are solid-state fermentation (SSF) and submerged liquid fermentation (SLF). SSF takes months, to develop this mushroom for their fruiting body generation. In contrast, other options are SLF, which can cut the period of getting their liquid mycelium biomass and polysaccharides to only several weeks (Cho et al., 2015). However, according to previous research, Repeated batch fermentation (RBF) is by all accounts the most encouraging liquid cultivation method as it can produce more biomass in a shorter time as compared to other type of fermentation.

RBF is an adjustment of a current method where the medium or a specific amount of a medium is expelled. Then, the new medium is presented intermittently or more than once without changing the current culture. The RBF appeared to be powerful

in enhancing microbial productivity (Birhanli & Yesilada, 2010; Wan Mohtar et al., 2016). Effective and efficient production of bioactive compounds such as polysaccharides and ganoderic acid from medicinal fungi is vital to meet the demands for various applications in the pharmaceutical industry and the cosmetics and personal care industries (Ahmad Usuldin et al., 2021).

In this study, our focus was on the production of exopolysaccharide (EPS) and endopolysaccharide (ENS) from Malaysian *Ganoderma lucidum* for the regulation of postprandial hyperglycaemia, focusing on inhibiting the  $\alpha$ -glucosidase enzyme mechanism.  $\alpha$ -glucosidase is an enzyme that catalyses the hydrolysis of starch to simple sugars for intestinal absorption, and the  $\alpha$ -glucosidase inhibitor (AGI) such as acarbose and miglitol are particularly advantageous for reducing postprandial blood glucose levels by delaying the digestion of carbohydrates into glucose. The synthetic antidiabetic drugs were reported to have many side effects on diabetic patients' health. The most often reported adverse effects of these medications are gastrointestinal problems. Acarbose lowers blood glucose by slowing down the carbohydrate's digestion. However, in the colon, the bacteria that degraded the undigested carbohydrates cause excessive gas formation, resulting in flatulence, diarrhoea, and abdominal pain (Akmal & Wadhwa, 2021). Other than that, these synthetic drugs also pose a distinct adverse effect on diabetic patients, including hypersensitivity reactions, lactic acidosis, liver failure, acute pancreatitis, and weight gain (Chaudhury et al., 2017). The limitation of these drugs concerning the significant side effects on the patient has paved the way to the search for alternative solutions, considering the use of natural products derived from medicinal mushrooms as a promising compound to treat diabetes.

This study explores the potential of polysaccharides extracted from Malaysian *Ganoderma lucidum* (GL) as a natural  $\alpha$ -glucosidase inhibitor. Reports have been made regarding the use of substances and extracts derived from GL as antidiabetic substances. GL has been shown previously to exert an antidiabetic effect; however, to date, an in-depth explanation of the mechanisms underlying its antidiabetic effect is still scarce (M. Liu et al., 2018).

## 1.2 PROBLEM STATEMENT

The conventional method of producing *Ganoderma lucidum*, which is solid-state fermentation (SLF), requires a time-consuming and lengthy incubation period. It takes several months for fruiting bodies to appear and extremely susceptible to contamination during that time. As a result, the repeated batch fermentation technique was used as an alternate method of producing an effective and efficient number of bioactive compounds in a shorter time in meeting the demands for a broad range of applications across sectors.

Current  $\alpha$ -glucosidase inhibitors that have been utilized to treat type 2 diabetes (T2D) cause adverse side effects, including diarrhoea, abdominal bloating, flatulence, and distention. Thus, an urgent need to search for natural  $\alpha$ -glucosidase inhibitors with no or fewer side effects. The polysaccharides extracted from *Ganoderma lucidum* have been proven to exhibit antidiabetic effects and play a role in blood glucose regulation. Hence, this study attempted to explore the *in vitro*  $\alpha$ -glucosidase inhibition activity of EPS-BG and ENS-BG from the mycelium of Malaysian *Ganoderma lucidum* strain QRS 5120. Furthermore, the *in vivo* effect of EPS-BG and ENS-BG in reducing the blood glucose level was analysed in induced diabetic adult zebrafish models, potentiating the use of these compounds as natural drugs in the treatment of type 2 diabetes.

## 1.3 RESEARCH OBJECTIVES

Generally, this study aims to identify the roles of EPS and ENS extracted from *Ganoderma lucidum* in inhibiting the  $\alpha$ -glucosidase enzyme with a specific objective listed below.

1. To identify the efficiency and morphological changes of Malaysian *Ganoderma lucidum* mycelium in a repeated batch fermentation for the production of EPS and ENS.

2. To demonstrate the *in vitro* natural  $\alpha$ -glucosidase inhibitory reaction of Exo- and Endo- $\beta$ -glucan from Malaysian *Ganoderma lucidum*.
3. To evaluate the *in vivo* effect of Exo- and Endo- $\beta$ -glucan in reducing the blood glucose level of induced diabetic adult zebrafish.

#### 1.4 HYPOTHESIS

1. RBF will improve the exopolysaccharide (EPS) and endopolysaccharide (ENS) production of *Ganoderma lucidum* strain QRS5120.
2. The Exo- and Endo- $\beta$ -glucan from *Ganoderma lucidum* strain QRS5120 inhibits the *in-vitro*  $\alpha$ -glucosidase enzyme activities.
3. The Exo- and Endo- $\beta$ -glucan from *Ganoderma lucidum* strain QRS5120 lowered the blood glucose level in induced diabetic adult zebrafish.

#### 1.5 SIGNIFICANCE OF THE STUDY

The ideal cultivation factors and conditions of RBF for *Ganoderma lucidum* strain QRS5120 can be used as a blueprint for an upscale bioreactor application in future use. The natural  $\alpha$ -glucosidase inhibitory reaction of Exo- and Endo- $\beta$ -glucan from Malaysian *Ganoderma lucidum* is crucial for developing new antidiabetic drugs ( $\alpha$ -glucosidase inhibitors) from a natural source which is a safe way to control Type 2 Diabetes (T2D) and effective compared to the conventional medicines.

## 1.6 CONCEPTUAL FRAMEWORK




Figure 1.1 Conceptual framework

## CHAPTER TWO

### LITERATURE REVIEW

#### 2.1 *Ganoderma lucidum*

In recent years, medicinal mushrooms have been extensively researched for their potential to alleviate disease, and they have been ingested throughout history, particularly in Asian countries (Seweryn et al., 2021). *Ganoderma lucidum* (GL) is a genus of Ganoderma from the Ganodermataceae family of Polyporales order that is included in the class of Agaricomycete from phylum Basidiomycota. Before, this mushroom is widely known and been recognised as ‘Lingzhi’ in China, but researchers recently discovered that ‘Lingzhi’ was different from the GL based on both morphological and molecular data (Dai et al., 2017). Lingzhi has traditionally been regarded as a magical herb as well as an auspicious emblem in Chinese culture (Z. Lin, 2019).

*Ganoderma lucidum* has been widely used for traditional medicine for over two thousand years and has proven to possess numerous therapeutic properties, including anti-cancer (Syairah et al., 2018; J. J. Zhang et al., 2021), anti-hyperglycaemic (Alzahrani & Pinto, 2021; Lee et al., 2020; Sarnthima et al., 2017; J. J. Zhang et al., 2021), antiviral (Wu et al., 2019), antibacterial (Savin et al., 2020; C. Wang et al., 2019), cardioprotective (Chan et al., 2021), and wound healing properties (Yin et al., 2019).

##### 2.1.1 *Ganoderma lucidum* Strain QRS 5120

*Ganoderma lucidum* strain QRS 5120 was morphologically identified and sequenced using phylogenetic software (Supramani, Ahmad, Ilham, et al., 2019). The study showed that the *Ganoderma lucidum* strain QRS 5120 was found to yield 637 base pairs, which was comparable to other Ganoderma species. The discovery of this novel strain sparked a flurry of investigations into a variety of fields and aspects. Supramani, Ahmad, & Wan-Mohtar, (2019) studied the antimicrobial effect of beta-glucan from *G. lucidum* QRS 5120 mycelium against four species of pathogenic bacteria (*S.*